Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis
Background and Objectives Isoniazid and rifampin are the first -line drugs against Mycobacterium tuberculosis . Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs. Materials and meth...
Gespeichert in:
| Veröffentlicht in: | Molecular biology reports 2023-12, Vol.50 (12), p.10271-10275 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10275 |
|---|---|
| container_issue | 12 |
| container_start_page | 10271 |
| container_title | Molecular biology reports |
| container_volume | 50 |
| creator | Hosseinali, Zahra Mohammadshahi, Jafar Teimourpour, Amir Habibzadeh, Shahram Esmaelizad, Majid Arzanlou, Mohsen Mirzanejad-Asl, Hafez Sadeghnezhad, Mahin Sohrabi, Shabnam Teimourpour, Roghayeh |
| description | Background and Objectives
Isoniazid and rifampin are the first -line drugs against
Mycobacterium tuberculosis
. Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs.
Materials and methods
In this descriptive cross-sectional study, 111 non - duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to the Ardabil Health Center between 2017 and 2020. The samples were first examined by microscopic method, then their DNA was extracted using the boiling method. Specific primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identification of MDR strain.
Results
of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%.
Conclusion
In our study, the prevalence of resistance to isoniazid and rifampin among
Mycobacterium tuberculosis
complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti- tuberculosis resistance rate among NTM compared to MTC strains. |
| doi_str_mv | 10.1007/s11033-023-08867-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2891755317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2893473009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-3fa5193343a6386a515d20594ecdf43982ea6ef720d0d77e0625caf5c7584c213</originalsourceid><addsrcrecordid>eNp9kE1LHTEUQEOp6Kv6B7ooA93oYvQmdzKZWRZbW8GHUOo65GXuSGRm8pqPhf_ePJ9toQsXIYScnCSHsY8cLjiAuoycA2INooyua1Wt3rEVlwrrplfde7YCBF43neRH7EOMjwDQcCUP2RGqXnHZtium134imycTKjfQktzorEnOL5UfqzlPyW0nqoaQH6pA0cVkFkvV2frrz_MqpmDcC7h-sn5jbKLg8lylvKFQnL7wJ-xgNFOk09f5mN1ff_t19aO-vft-c_XltrYo2lTjaCTvERs0LXZtWchBgOwbssPYYN8JMi2NSsAAg1IErZDWjNIq2TVWcDxmZ3vvNvjfmWLSs4uWpsks5HPUouvL1yVyVdDP_6GPPoelvG5HYaMQoC-U2FM2-BgDjXob3GzCk-agd_n1Pr8u-fVLfr1Tf3pV581Mw98jf3oXAPdALFvLA4V_d7-hfQbwDY-8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2893473009</pqid></control><display><type>article</type><title>Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Hosseinali, Zahra ; Mohammadshahi, Jafar ; Teimourpour, Amir ; Habibzadeh, Shahram ; Esmaelizad, Majid ; Arzanlou, Mohsen ; Mirzanejad-Asl, Hafez ; Sadeghnezhad, Mahin ; Sohrabi, Shabnam ; Teimourpour, Roghayeh</creator><creatorcontrib>Hosseinali, Zahra ; Mohammadshahi, Jafar ; Teimourpour, Amir ; Habibzadeh, Shahram ; Esmaelizad, Majid ; Arzanlou, Mohsen ; Mirzanejad-Asl, Hafez ; Sadeghnezhad, Mahin ; Sohrabi, Shabnam ; Teimourpour, Roghayeh</creatorcontrib><description>Background and Objectives
Isoniazid and rifampin are the first -line drugs against
Mycobacterium tuberculosis
. Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs.
Materials and methods
In this descriptive cross-sectional study, 111 non - duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to the Ardabil Health Center between 2017 and 2020. The samples were first examined by microscopic method, then their DNA was extracted using the boiling method. Specific primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identification of MDR strain.
Results
of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%.
Conclusion
In our study, the prevalence of resistance to isoniazid and rifampin among
Mycobacterium tuberculosis
complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti- tuberculosis resistance rate among NTM compared to MTC strains.</description><identifier>ISSN: 0301-4851</identifier><identifier>EISSN: 1573-4978</identifier><identifier>DOI: 10.1007/s11033-023-08867-7</identifier><identifier>PMID: 37971566</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animal Anatomy ; Animal Biochemistry ; Antitubercular Agents - pharmacology ; Biomedical and Life Sciences ; Bronchus ; Cross-Sectional Studies ; Drug resistance ; Drug Resistance, Multiple ; Drugs ; Extracellular Matrix Biology ; Histology ; Humans ; Isoniazid ; Isoniazid - pharmacology ; Lavage ; Life Sciences ; Microbial Sensitivity Tests ; Morphology ; Multidrug resistance ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - genetics ; Original Article ; Polymerase chain reaction ; Public health ; Rifampin ; Rifampin - pharmacology ; Sputum ; Tuberculosis</subject><ispartof>Molecular biology reports, 2023-12, Vol.50 (12), p.10271-10275</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Nature B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-3fa5193343a6386a515d20594ecdf43982ea6ef720d0d77e0625caf5c7584c213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11033-023-08867-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11033-023-08867-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37971566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hosseinali, Zahra</creatorcontrib><creatorcontrib>Mohammadshahi, Jafar</creatorcontrib><creatorcontrib>Teimourpour, Amir</creatorcontrib><creatorcontrib>Habibzadeh, Shahram</creatorcontrib><creatorcontrib>Esmaelizad, Majid</creatorcontrib><creatorcontrib>Arzanlou, Mohsen</creatorcontrib><creatorcontrib>Mirzanejad-Asl, Hafez</creatorcontrib><creatorcontrib>Sadeghnezhad, Mahin</creatorcontrib><creatorcontrib>Sohrabi, Shabnam</creatorcontrib><creatorcontrib>Teimourpour, Roghayeh</creatorcontrib><title>Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis</title><title>Molecular biology reports</title><addtitle>Mol Biol Rep</addtitle><addtitle>Mol Biol Rep</addtitle><description>Background and Objectives
Isoniazid and rifampin are the first -line drugs against
Mycobacterium tuberculosis
. Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs.
Materials and methods
In this descriptive cross-sectional study, 111 non - duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to the Ardabil Health Center between 2017 and 2020. The samples were first examined by microscopic method, then their DNA was extracted using the boiling method. Specific primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identification of MDR strain.
Results
of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%.
Conclusion
In our study, the prevalence of resistance to isoniazid and rifampin among
Mycobacterium tuberculosis
complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti- tuberculosis resistance rate among NTM compared to MTC strains.</description><subject>Animal Anatomy</subject><subject>Animal Biochemistry</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Biomedical and Life Sciences</subject><subject>Bronchus</subject><subject>Cross-Sectional Studies</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple</subject><subject>Drugs</subject><subject>Extracellular Matrix Biology</subject><subject>Histology</subject><subject>Humans</subject><subject>Isoniazid</subject><subject>Isoniazid - pharmacology</subject><subject>Lavage</subject><subject>Life Sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Morphology</subject><subject>Multidrug resistance</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Original Article</subject><subject>Polymerase chain reaction</subject><subject>Public health</subject><subject>Rifampin</subject><subject>Rifampin - pharmacology</subject><subject>Sputum</subject><subject>Tuberculosis</subject><issn>0301-4851</issn><issn>1573-4978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kE1LHTEUQEOp6Kv6B7ooA93oYvQmdzKZWRZbW8GHUOo65GXuSGRm8pqPhf_ePJ9toQsXIYScnCSHsY8cLjiAuoycA2INooyua1Wt3rEVlwrrplfde7YCBF43neRH7EOMjwDQcCUP2RGqXnHZtium134imycTKjfQktzorEnOL5UfqzlPyW0nqoaQH6pA0cVkFkvV2frrz_MqpmDcC7h-sn5jbKLg8lylvKFQnL7wJ-xgNFOk09f5mN1ff_t19aO-vft-c_XltrYo2lTjaCTvERs0LXZtWchBgOwbssPYYN8JMi2NSsAAg1IErZDWjNIq2TVWcDxmZ3vvNvjfmWLSs4uWpsks5HPUouvL1yVyVdDP_6GPPoelvG5HYaMQoC-U2FM2-BgDjXob3GzCk-agd_n1Pr8u-fVLfr1Tf3pV581Mw98jf3oXAPdALFvLA4V_d7-hfQbwDY-8</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Hosseinali, Zahra</creator><creator>Mohammadshahi, Jafar</creator><creator>Teimourpour, Amir</creator><creator>Habibzadeh, Shahram</creator><creator>Esmaelizad, Majid</creator><creator>Arzanlou, Mohsen</creator><creator>Mirzanejad-Asl, Hafez</creator><creator>Sadeghnezhad, Mahin</creator><creator>Sohrabi, Shabnam</creator><creator>Teimourpour, Roghayeh</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20231201</creationdate><title>Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis</title><author>Hosseinali, Zahra ; Mohammadshahi, Jafar ; Teimourpour, Amir ; Habibzadeh, Shahram ; Esmaelizad, Majid ; Arzanlou, Mohsen ; Mirzanejad-Asl, Hafez ; Sadeghnezhad, Mahin ; Sohrabi, Shabnam ; Teimourpour, Roghayeh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-3fa5193343a6386a515d20594ecdf43982ea6ef720d0d77e0625caf5c7584c213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animal Anatomy</topic><topic>Animal Biochemistry</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Biomedical and Life Sciences</topic><topic>Bronchus</topic><topic>Cross-Sectional Studies</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple</topic><topic>Drugs</topic><topic>Extracellular Matrix Biology</topic><topic>Histology</topic><topic>Humans</topic><topic>Isoniazid</topic><topic>Isoniazid - pharmacology</topic><topic>Lavage</topic><topic>Life Sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Morphology</topic><topic>Multidrug resistance</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Original Article</topic><topic>Polymerase chain reaction</topic><topic>Public health</topic><topic>Rifampin</topic><topic>Rifampin - pharmacology</topic><topic>Sputum</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hosseinali, Zahra</creatorcontrib><creatorcontrib>Mohammadshahi, Jafar</creatorcontrib><creatorcontrib>Teimourpour, Amir</creatorcontrib><creatorcontrib>Habibzadeh, Shahram</creatorcontrib><creatorcontrib>Esmaelizad, Majid</creatorcontrib><creatorcontrib>Arzanlou, Mohsen</creatorcontrib><creatorcontrib>Mirzanejad-Asl, Hafez</creatorcontrib><creatorcontrib>Sadeghnezhad, Mahin</creatorcontrib><creatorcontrib>Sohrabi, Shabnam</creatorcontrib><creatorcontrib>Teimourpour, Roghayeh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular biology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hosseinali, Zahra</au><au>Mohammadshahi, Jafar</au><au>Teimourpour, Amir</au><au>Habibzadeh, Shahram</au><au>Esmaelizad, Majid</au><au>Arzanlou, Mohsen</au><au>Mirzanejad-Asl, Hafez</au><au>Sadeghnezhad, Mahin</au><au>Sohrabi, Shabnam</au><au>Teimourpour, Roghayeh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis</atitle><jtitle>Molecular biology reports</jtitle><stitle>Mol Biol Rep</stitle><addtitle>Mol Biol Rep</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>50</volume><issue>12</issue><spage>10271</spage><epage>10275</epage><pages>10271-10275</pages><issn>0301-4851</issn><eissn>1573-4978</eissn><abstract>Background and Objectives
Isoniazid and rifampin are the first -line drugs against
Mycobacterium tuberculosis
. Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs.
Materials and methods
In this descriptive cross-sectional study, 111 non - duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to the Ardabil Health Center between 2017 and 2020. The samples were first examined by microscopic method, then their DNA was extracted using the boiling method. Specific primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identification of MDR strain.
Results
of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%.
Conclusion
In our study, the prevalence of resistance to isoniazid and rifampin among
Mycobacterium tuberculosis
complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti- tuberculosis resistance rate among NTM compared to MTC strains.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>37971566</pmid><doi>10.1007/s11033-023-08867-7</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-4851 |
| ispartof | Molecular biology reports, 2023-12, Vol.50 (12), p.10271-10275 |
| issn | 0301-4851 1573-4978 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2891755317 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Animal Anatomy Animal Biochemistry Antitubercular Agents - pharmacology Biomedical and Life Sciences Bronchus Cross-Sectional Studies Drug resistance Drug Resistance, Multiple Drugs Extracellular Matrix Biology Histology Humans Isoniazid Isoniazid - pharmacology Lavage Life Sciences Microbial Sensitivity Tests Morphology Multidrug resistance Mycobacterium tuberculosis Mycobacterium tuberculosis - genetics Original Article Polymerase chain reaction Public health Rifampin Rifampin - pharmacology Sputum Tuberculosis |
| title | Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A05%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20identification%20of%20multiple%20drug%20resistance%20(MDR)%20strain%20of%20Mycobacterium%20tuberculosis&rft.jtitle=Molecular%20biology%20reports&rft.au=Hosseinali,%20Zahra&rft.date=2023-12-01&rft.volume=50&rft.issue=12&rft.spage=10271&rft.epage=10275&rft.pages=10271-10275&rft.issn=0301-4851&rft.eissn=1573-4978&rft_id=info:doi/10.1007/s11033-023-08867-7&rft_dat=%3Cproquest_cross%3E2893473009%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2893473009&rft_id=info:pmid/37971566&rfr_iscdi=true |